Review rates Vaxzevria alongside mRNA jabs in stopping serious COVID-19

An expert review of data from 79 real-world studies showed that AstraZeneca’s (LSE: AZN) COVID-19 vaccine, Vaxzevria (ChAdOx1-S [recombinant]) and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalization and death from COVID-19 following two doses.

Data from the VIEW-hub database on vaccine use and impact, developed by Johns Hopkins Bloomberg School of Public Health and the International Vaccine Access Center, was reviewed by infectious disease experts from across Asia. The study findings were reported by Expert Review of Vaccines.

"This is important information for policymakers as they consider the optimal deployment of COVID-19 vaccines in their populations over the next 12 months"The study shows that Vaxzevria and the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines offer an equivalent degree of protection against hospitalization and death, both of between 91% and 93%, regardless of age.